Calls Bought on Exelixis (EXEL)

Loading...
Loading...
Shares of Exelixis
EXEL
are higher on the session by 6.47%, currently trading $5.43. The stock is popping today after the company said they were going to raise $160 million to repay obligations under a loan from GlaxoSmithKline. Options traders are coming after calls in the name with the August $7.50 call purchased over 5,500 times today; open interest on the strike is 12,427 contracts. Call volume is now running at over 20x the daily average with 90% of all calls traded being purchases on the offer. Exelixis, Inc. is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on discovery and development of small molecule drugs for cancer.
Date of Trade
ticker
Put/Call
Strike Price
DTE
Sentiment
Posted In: Long IdeasTechnicalsOptionsTrading IdeasGlaxoSmithKline PLCHealth CareLife Sciences Tools & Services
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...